Patient Switching Behaviors Impact on Adherence and Engagement: A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes Today we have access to more data, from more sources than we could ever…
This summary provides highlights from robust longitudinal insights reports released throughout the year and available at our INTELLICENTER® portal. The Brand Access Marketplace Dynamics reports identify current and future access landscapes providing insights to support effective…
We Are Uniquely Positioned To Deliver EVERSANA is uniquely positioned to follow the trends and introduce new models and strategies to maximize the value of pharmaceutical products through Digital Medicine Solutions and Execution. Digital Solutions…
As the public health pandemic spreads, EVERSANA has identified challenges facing clinical trial participation, and how these challenges will impact patients now and following the COVID-19 pandemic. […] Supporting patients and providing them with valuable information…
In the midst of a global pandemic, the role of commercial field teams evolved right before our eyes. Digital sales aids and tele-detailing are now mandatory sales tactics in a virtual Provider-Rep engagement. Now that field…
Last August, Canada’s Patented Medicine Prices Review Board (PMPRB) announced a set of amendments for its regulatory measures, in a bid to strengthen and modernize the country’s pricing framework for patented drugs. Following the initial proposal…
Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!
In February 2020, healthcare as we knew it changed. The industry began waging an aggressive war with an unknown virus beginning to overwhelm hospitals on a global scale. We immediately recognized that we needed to do…
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug Administration (FDA)-approved oncolytic biosimilars in the…
Improving Patient Adherence With Behavioral Health Technology The industry’s shift to outcomes-based, patient-centered care requires new approaches to patient support to achieve adherence and therapeutic success. Today’s patients are also highly motivated information seekers and are…
IF I COULD ONLY ASK TWO QUESTIONS, THE FIRST WOULD BE: What is your data integration and analytics platform strategy? As the industry continues its shift to a patient-centric, value-based model of care, it is critical…
